Trial · NCT03186378
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment / Yes | 0 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) Pre-treatment / No | 16 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment / Yes | 1 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 2hr Post Treatment / No | 15 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment / Yes | 0 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 6hr Post Treatment / No | 16 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment / Yes | 0 | Participants | |
| The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following Treatment of VP-102. | Exposure Group | Any Concentration Level of VP-102 above LLOQ (2.5ng/ml) 24hr Post Treatment / No | 16 | Participants | |
| Measurement of Efficacy - Complete Clearance | Exposure Group | Complete Clearance Day 21 | 0 | Participants | |
| Measurement of Efficacy - Complete Clearance | Standard Group | Complete Clearance Day 21 | 3 | Participants | |
| Measurement of Efficacy - Complete Clearance | Exposure Group | Complete Clearance Day 42 | 2 | Participants | |
| Measurement of Efficacy - Complete Clearance | Standard Group | Complete Clearance Day 42 | 7 | Participants | |
| Measurement of Efficacy - Complete Clearance | Exposure Group | Complete Clearance Day 63 | 4 | Participants | |
| Measurement of Efficacy - Complete Clearance | Standard Group | Complete Clearance Day 63 | 9 | Participants | |
| Measurement of Efficacy - Complete Clearance | Exposure Group | Complete Clearance EOS Day 84 | 6 | Participants | |
| Measurement of Efficacy - Complete Clearance | Standard Group | Complete Clearance EOS Day 84 | 10 | Participants | |
| Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit. | Exposure Group | >=90% Clearance Day 21 | 0 | Participants | |
| Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit. | Standard Group | >=90% Clearance Day 21 | 3 | Participants | |
| Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit. | Exposure Group | >=90% Clearance Day 42 | 5 | Participants | |
| Proportion of Subjects Exhibiting a 90% or Greater Reduction of All Treated Molluscum Lesions (Baseline and New) at the EOS Visit. | Standard Group | >=90% Clearance Day 42 | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03186378/results